Synthis Therapeutics
Developing a first in class therapeutic platform that rescues immune function and drives tumor clearance in advanced cancer patients
WHO WE ARE
Dynamic therapeutics immuno-oncology startup in NYC. Synthis’s team is a talented group of scientists with a groundbreaking idea to improve patient care and outcomes. As long-standing tumor immunologists, the team is passionate about the science and therapeutic power behind restoring immune function in cancer patients.
Technology
Synthis Therapeutics is an early-stage biotech company dedicated to the innovation of targeted therapies that harnesses the power of patients’ own immune system to eliminate metastatic cancer. Our novel therapeutic platform evolved from an idea to develop safer and more efficacious therapies that eliminate one of the most immunosuppressive pathways in virtually all cancers, known as TGF-β. By developing therapies that selectively target the immunosuppressive arm of the TGF-β pathway, we can safely drive efficacy and patient survival
TIMELINE
2017
2018
2019
2020
Synthis Therapeutics was founded
& therapeutics platform biology developed virtually
Women In Bio Founders Scholarship Award
NCI Phase I SBIR Award
ELab NYC Accelerator Program Fellow
Alexandria LaunchLabs Member Company
Annual Alexandria Life Science Summit Pitch
NCI Phase I SBIR Award
J&J Innovation Showcase Company
Springboard Enterprises Life Science Track Observer
Annual BIO CEO & Investor Conference: NYC-EDC selected company
Annual BIO Conference NIH Sponsored Company Presentation
Endless Frontiers Lab Accelerator Program
CONTACT US
430 E. 29th Street
Alexandria LaunchLabs, 14th Floor
New York, New York
10016
917-837-8796